Clinical chemistry & immunoassay reagents and analyzers
Active Purchase Order Awarded Last action
- Contract number
- W81K0222P0104
- Awardee
-
Roche Diagnostics Corporation UEI JDMDFEZBYH36
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $3,009,762
Award facts
- Opportunity
-
- Clinical Chemistry and Immunoassay Reagents and Abbott Analyzers Pre-Solicitation · W81K0222Q0108 · Posted Jun 15, 2022
- Contract value 65% obligated
- $4,665,198.25 Current and potential, with all options
- Completion date 82% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 5 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Castleton, IN 46256, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $100,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $1,415,436 | |
| Supplemental Agreement for work within scope | -$150,038 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $194,928 | |
| Supplemental Agreement for work within scope | $1,220,507 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | -$135,000 | |
| Supplemental Agreement for work within scope | -$165,000 | |
| Supplemental Agreement for work within scope | -$165,000 | |
| Supplemental Agreement for work within scope | -$276,579 | |
| Supplemental Agreement for work within scope | -$485,507 | |
| Funding Only Action | $1,220,507 | |
| Supplemental Agreement for work within scope | -$235,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | -$250,000 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | -$500,000 | |
| Funding Only Action | $1,220,507 | |
| Original award | $0 |
Show all 23
About this award
Defense Health Agency awarded a purchase order to Roche Diagnostics Corporation for clinical chemistry and immunoassay reagents and analyzers, valued at $4,665,198.25, with an award date of October 1, 2022 and ultimate completion date of September 30, 2027. Performance takes place in Castleton, Indiana. The order covers Roche Diagnostics clinical chemistry and immunoassay reagents under firm fixed-price terms. The procurement originated from a pre-solicitation notice posted June 15, 2022 by Tripler Army Medical Center, Hawaii, which sought Abbott clinical chemical and immunoassay reagents and analyzers; the final award went to Roche Diagnostics for similar capability, indicating the Government's determination of appropriate acquisition method following the sources-sought phase.
Quick answers
Who was awarded contract W81K0222P0104?
W81K0222P0104 was awarded to Roche Diagnostics Corporation by Defense Health Agency (Department of Defense) on October 1, 2022.
How much is contract W81K0222P0104 worth?
The government has obligated $3,009,762 on W81K0222P0104. Its current value, with exercised options, is $4,665,198.
Was contract W81K0222P0104 competed?
The extent of competition for W81K0222P0104 was competed under sap. The government received 5 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award